Cervical cancer is the third most common malignancy in women worldwide. New information on the causal role of human papillomavirus (HPV) infection, and the availability of new cervical cancer screening options, raise important clinical and policy questions. The purpose of this project is to develop a Global Cervical Cancer Policy Model to address such questions in both developed and developing countries, in which differences in disease burden, health-care priorities, and economic resources will mandate consideration of different cancer control strategies. In the U.S., cervical cytology screening has reduced cancer incidence, however, has not been equally accessible to all groups of women. For women who are older, poor, or from select cultural minorities, there is a need to evaluate new strategies for increasing screening coverage. On the national level, the most pressing policy questions relate to the economic consequences of current screening programs and how to best utilize newer screening technologies, such as enhanced cytologic methods and HPV DNA testing. In developing countries, such as South and East Africa, the critical policy issue is how to realistically implement cervical cancer screening programs in the setting of competing health issues and limited healthcare and monetary resources. Recent clinical studies have shown promising results for less complex screening strategies, such as simple visual screening methods or HPV DNA testing followed by immediate treatment without colposcopic triage However, these noncytological screening strategies need to be formally evaluated to determine if they can be implemented and sustained for a cost acceptable to developing countries.
The specific aims of this project are: (1) To develop a probabilistic cervical cancer model incorporating new epidemiological data on the natural history of HPV; (2) To evaluate the health and economic consequences of alternative cervical cancer screening strategies in the U.S., focusing on subpopulations at particularly high-risk and readdressing optimal target ages, screening intervals and use of new technology; (3) To assess the cost-effectiveness of alternative cervical cancer screening and prevention strategies for previously unscreened women in South Africa and Zimbabwe, incorporating the impact of REV, and considering the health-infrastructure and per-capita health expenditure in each country. This project will bring together a team of diverse investigators with complementary areas of expertise to develop a comprehensive, state-of-the-art, Global Cervical Cancer Policy Model. The proposed analyses will provide important information to clinicians, public health providers, and policy makers in both the national and international arena.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA093435-01
Application #
6417209
Study Section
Special Emphasis Panel (ZRG1-SNEM-4 (01))
Program Officer
Brown, Martin L
Project Start
2002-05-07
Project End
2005-02-28
Budget Start
2002-05-07
Budget End
2003-02-28
Support Year
1
Fiscal Year
2002
Total Cost
$357,384
Indirect Cost
Name
Harvard University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02115
Burger, E A; Ortendahl, J D; Sy, S et al. (2012) Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer 106:1571-8
Goldie, Sue J; O'Shea, Meredith; Kim, Jane J (2012) Finding consensus on cervical cancer prevention. Am J Public Health 102:1050-1; author reply 1051
Campos, Nicole G; Castle, Philip E; Schiffman, Mark et al. (2012) Policy implications of adjusting randomized trial data for economic evaluations: a demonstration from the ASCUS-LSIL Triage Study. Med Decis Making 32:400-27
Campos, Nicole G; Kim, Jane J; Castle, Philip E et al. (2012) Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer 130:2672-84
Price, Rebecca Anhang; Frank, Richard G; Cleary, Paul D et al. (2011) Effects of direct-to-consumer advertising and clinical guidelines on appropriate use of human papillomavirus DNA tests. Med Care 49:132-8
Goldie, Sue J; Daniels, Norman (2011) Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparities. J Natl Cancer Inst 103:1373-86
Campos, Nicole G; Rodriguez, Ana Cecilia; Castle, Philip E et al. (2011) Persistence of concurrent infections with multiple human papillomavirus types: a population-based cohort study. J Infect Dis 203:823-7
Goldhaber-Fiebert, Jeremy D; Stout, Natasha K; Goldie, Sue J (2010) Empirically evaluating decision-analytic models. Value Health 13:667-74
Kim, Jane J (2010) Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 10:845-52
Kim, Jane J; Ortendahl, Jesse; Goldie, Sue J (2009) Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 151:538-45

Showing the most recent 10 out of 35 publications